<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453490</url>
  </required_header>
  <id_info>
    <org_study_id>CRCLM-01</org_study_id>
    <nct_id>NCT02453490</nct_id>
  </id_info>
  <brief_title>Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis</brief_title>
  <official_title>The Second Affiliated Hospital of Zhejiang University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter ,randomization, open control study to evaluate the efficacy and
      safety of Raltitrexed-based chemotherapy and 5-fluorouracil-based chemotherapy in the
      peri-operative treatment of patients with Liver Metastasis From colorectal cancer (CRC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The contrast analysis is separately done on Raltitrexed plus oxaliplatin and 5-fluorouracil
      plus oxaliplatin;Raltitrexed plus irinotecan and 5-fluorouracil plus irinotecan.To
      investigate the objective response rate,the R0 resection rate, the early tumor shrinkage
      （ETS）and depth of response(DPR) and the safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>38 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate of liver</measure>
    <time_frame>38 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The side effects of the treatment</measure>
    <time_frame>38 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The early tumor shrinkage （ETS）and depth of response(DPR)</measure>
    <time_frame>38 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Raltitrexed-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil-based chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed-based chemotherapy</intervention_name>
    <description>Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w</description>
    <arm_group_label>Raltitrexed-based chemotherapy</arm_group_label>
    <other_name>RTXOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed-based chemotherapy</intervention_name>
    <description>Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w</description>
    <arm_group_label>Raltitrexed-based chemotherapy</arm_group_label>
    <other_name>RTXIRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil-based chemotherapy</intervention_name>
    <description>5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w</description>
    <arm_group_label>5-fluorouracil-based chemotherapy</arm_group_label>
    <other_name>mFOLFOX6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil-based chemotherapy</intervention_name>
    <description>5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w</description>
    <arm_group_label>5-fluorouracil-based chemotherapy</arm_group_label>
    <other_name>FOLFIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed chinese colorectal cancer patients and imaging detection
             confirmed liver metastasis

          2. previously no treatment for liver metastasis or Primary tumor had been removed and
             last additional chemotherapy over one year

          3. Age of≥18 and ≤75

          4. Adequate organ functions, as determined by normal bone marrow function (absolute
             neutrophil count2 x 109/L, platelets 100 x 109/L, White blood cells 4 x 109/L), liver
             function (serum bilirubin ≤ 2.5 x ULN, serum transaminases ≤2. 5x ULN)

          5. ECOG≤1

          6. Life Expectancy＞6months

          7. Signed written informed consent

          8. Expected adequacy of follow-up

        Exclusion Criteria:

          1. Lesion is too small to assess by imaging

          2. Extrahepatic metastases

          3. Any anticancer chemotherapy in development within 4 weeks prior to study entry

          4. Concurrent uncontrolled illness such as infection

          5. Be allergic to medicines in the study

          6. Pregnant or nursing patients

          7. Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception.

          8. Not willing or incapable to comply with all study visits and assessments

          9. Evidence of any other disease, metabolic dysfunction, physical examination finding or
             laboratory finding giving reasonable suspicion of a disease or condition that puts the
             patient at high risk for treatment-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding Ke-Feng, PHD/MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Shao-Jun, MD</last_name>
    <phone>0571-87784760</phone>
    <email>ysjzlwk@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Zhongshan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zhi-Zhong Pan, MD/PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kai-Xiong Tao, MD/PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital Affiliated to Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bing Xiong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wei Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jianjiang Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospitalof Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke-Feng Ding, PhD/MD</last_name>
      <phone>86-571-87784827</phone>
      <email>dingkefeng@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ke-Feng Ding, PhD/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xuefeng Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinhua People's Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jinlin Du, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Ningbo City</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xiao-Yu Dai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ding Ke-Feng</investigator_full_name>
    <investigator_title>the Second Affiliated Hospital of Zhejiang University</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

